NERLYNX is being made available in Thailand by an Australian-headquartered company, Specialised Therapeutics, under an exclusive licensing arrangement. The therapy was approved by the TGA in 2019 but is not reimbursed via the PBS.
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Algorae names Nasdaq pharmaceutical chairman to strengthen board
July 15, 2026 - - Australian Biotech -
Starpharma raises $32 Million to advance dendrimer cancer programs
July 15, 2026 - - Australian Biotech -
Minister recommits to keeping MS medicines on the PBS while awaiting formal advice
July 15, 2026 - - Latest News -
Budget outlook now hangs on disability savings, but what about pharmaceuticals
July 15, 2026 - - Latest News -
Australian partnership advances gene therapy for Retinitis Pigmentosa
July 15, 2026 - - Latest News -
Patients move to reclaim access agenda ahead of sector negotiations
July 15, 2026 - - Latest News -
An opportunity to become a global destination for paediatric oncology trials
July 15, 2026 - - Latest News

